Journal of Controlled Release

Global Microneedle Drug Delivery Systems Market Report 2023: Sector is Expected to Reach $9.46 Billion by 2030 at a CAGR of 7.4% - ResearchAndMarkets.com

Retrieved on: 
Monday, July 3, 2023

The "Microneedle Drug Delivery Systems Market Size, Share & Trends Analysis Report By Type (Solid, Hollow), By Material (Silicon, Metal), By Application (Dermatology, Drug Delivery), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Microneedle Drug Delivery Systems Market Size, Share & Trends Analysis Report By Type (Solid, Hollow), By Material (Silicon, Metal), By Application (Dermatology, Drug Delivery), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global microneedle drug delivery systems market size is expected to reach USD 9.46 billion by 2030, registering a CAGR of 7.4% from 2023 to 2030.
  • Growing demand for safer alternatives to conventional hypodermic injection and increasing awareness about minimally invasive and pain-free administration of drugs is expected to boost the market growth for microneedle drug delivery systems.
  • The pandemic has also disrupted global supply chains, which has affected the production and distribution of microneedle-based drug delivery systems.

PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers

Retrieved on: 
Monday, December 19, 2022

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221219005209/en/
    PureTech announced topline results for LYT-300 (oral allopregnanolone), a therapeutic candidate in development for neurological and neuropsychological conditions.
  • The results show that oral administration of LYT-300 achieved blood levels of allopregnanolone at or above those associated with therapeutic benefit and results in exposure-dependent target engagement of GABAA receptors.
  • The impact of LYT-300 on b-EEG and other markers of GABAA target engagement were also assessed.
  • PureTech completed a Phase 1 clinical trial of LYT-300 in 2022, which demonstrated oral bioavailability, tolerability and GABAA receptor target engagement in healthy volunteers.

PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ Platform

Retrieved on: 
Wednesday, November 30, 2022

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221130005402/en/
    PureTech announced the nomination of a new therapeutic candidate, LYT-310, which is an oral cannabidiol (CBD) prodrug and the second therapeutic candidate developed from PureTechs Glyph platform to be advanced toward the clinic.
  • The nomination of LYT-310 is an exciting expansion of PureTechs Glyph technology, said Daniel Bonner, Ph.D., Vice President at PureTech Health.
  • Glyph is PureTechs synthetic lymphatic-targeting chemistry platform which is designed to employ the lymphatic systems natural lipid absorption and transport process to enable the oral administration of certain therapeutics.
  • A second therapeutic candidate, LYT-310 (oral cannabidiol), is expected to enter the clinic in Q4 of 2023.

PureTech Announces Publication of Research from Collaborators Demonstrating PureTech’s Glyph™ Platform Enhances Oral Absorption of Buprenorphine (a Clinically-Validated Opioid Replacement Therapy)

Retrieved on: 
Tuesday, April 12, 2022

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220411005986/en/
    PureTech announced the publication of preclinical proof-of-concept showing up to 20-fold oral bioavailability enhancement by the Glyph platform of buprenorphine, a clinically-validated opioid replacement therapy.
  • Results from this study further amplify the breadth of the Glyph delivery technology and its ability to use new chemistry and molecules for versatile applications.
  • The Glyph technology generates novel orally dosed prodrugs by reversibly linking small molecule drugs to dietary fat molecules.
  • PureTechs LYT-300 is the first therapeutic candidate generated by the Glyph technology platform to enter the clinic.